D&D Pharmatech (347850.KQ)

KRW 47200.0

(0.21%)

Operating Expenses Summary of D&D Pharmatech

  • D&D Pharmatech's latest annual operating expenses in 2023 was 32.16 Billion KRW , down -53.56% from previous year.
  • D&D Pharmatech's latest quarterly operating expenses in 2024 Q2 was 8.26 Billion KRW , up 25.58% from previous quarter.
  • D&D Pharmatech reported a annual operating expenses of 69.26 Billion KRW in annual operating expenses 2022, down -10.1% from previous year.
  • D&D Pharmatech reported a annual operating expenses of 77.04 Billion KRW in annual operating expenses 2021, up 11.48% from previous year.
  • D&D Pharmatech reported a quarterly operating expenses of 6.58 Billion KRW for 2024 Q1, up 13.74% from previous quarter.
  • D&D Pharmatech reported a quarterly operating expenses of 5.78 Billion KRW for 2023 Q4, down -17.41% from previous quarter.

Annual Operating Expenses Chart of D&D Pharmatech (2023 - 2019)

Historical Annual Operating Expenses of D&D Pharmatech (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 32.16 Billion KRW -53.56%
2022 69.26 Billion KRW -10.1%
2021 77.04 Billion KRW 11.48%
2020 69.1 Billion KRW 1426.28%
2019 4.52 Billion KRW 0.0%

Peer Operating Expenses Comparison of D&D Pharmatech

Name Operating Expenses Operating Expenses Difference
HLB Co., Ltd. 109.98 Billion KRW 70.757%
iNtRON Biotechnology, Inc. 7.84 Billion KRW -309.941%
BINEX Co., Ltd. 55.67 Billion KRW 42.231%
Bioneer Corporation 204.55 Billion KRW 84.277%
Anterogen.Co.,Ltd. 7.74 Billion KRW -315.536%
MEDIPOST Co., Ltd. 65.31 Billion KRW 50.757%
CrystalGenomics, Inc. 32.36 Billion KRW 0.638%
Helixmith Co., Ltd 37.36 Billion KRW 13.927%
Chabiotech Co.,Ltd. 285.93 Billion KRW 88.752%
Medy-Tox Inc. 110.88 Billion KRW 70.994%
Peptron, Inc. 16.65 Billion KRW -93.097%
Amicogen, Inc. 52.82 Billion KRW 39.112%
Genexine, Inc. 41.62 Billion KRW 22.737%
HLB Therapeutics Co.,Ltd. 16.16 Billion KRW -98.95%
LegoChem Biosciences, Inc. 98.61 Billion KRW 67.387%
ALTEOGEN Inc. 40.93 Billion KRW 21.429%
PharmaResearch Co., Ltd. 89.44 Billion KRW 64.04%
SillaJen, Inc. 5.11 Billion KRW -529.142%
JETEMA, Co., Ltd. 25.66 Billion KRW -25.323%
OliX Pharmaceuticals,Inc 35.24 Billion KRW 8.756%
Genomictree Inc. 16.26 Billion KRW -97.747%
MedPacto, Inc. 26.91 Billion KRW -19.48%
EASY BIO,Inc. 29.67 Billion KRW -8.396%
GI Innovation, Inc. 57.59 Billion KRW 44.154%